Telomir Pharmaceuticals (NASDAQ:TELO) Issues Earnings Results, Beats Expectations By $0.01 EPS

Telomir Pharmaceuticals (NASDAQ:TELO) posted its earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01, FiscalAI reports.

Telomir Pharmaceuticals Trading Up 0.7%

Shares of NASDAQ TELO traded up $0.01 during midday trading on Tuesday, reaching $1.35. The company had a trading volume of 35,742 shares, compared to its average volume of 126,783. Telomir Pharmaceuticals has a 1 year low of $1.05 and a 1 year high of $4.81. The business’s 50-day simple moving average is $1.27 and its 200 day simple moving average is $1.36. The stock has a market cap of $46.41 million, a P/E ratio of -3.65 and a beta of -0.66.

Wall Street Analyst Weigh In

Several analysts have commented on TELO shares. Rodman & Renshaw started coverage on shares of Telomir Pharmaceuticals in a research report on Tuesday, January 13th. They set a “buy” rating for the company. Wall Street Zen upgraded shares of Telomir Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold”.

Hedge Funds Weigh In On Telomir Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. XTX Topco Ltd acquired a new stake in Telomir Pharmaceuticals during the 4th quarter worth about $53,000. Geode Capital Management LLC increased its holdings in shares of Telomir Pharmaceuticals by 14.0% in the fourth quarter. Geode Capital Management LLC now owns 223,549 shares of the company’s stock valued at $297,000 after purchasing an additional 27,519 shares during the period. Raymond James Financial Inc. increased its holdings in shares of Telomir Pharmaceuticals by 4,101.9% in the third quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock valued at $105,000 after purchasing an additional 73,547 shares during the period. Jane Street Group LLC purchased a new position in shares of Telomir Pharmaceuticals in the second quarter worth about $62,000. Finally, Qube Research & Technologies Ltd purchased a new position in shares of Telomir Pharmaceuticals in the second quarter worth about $33,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.